BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

791 related articles for article (PubMed ID: 17877886)

  • 1. An update on short-course episodic and prevention therapies for herpes genitalis.
    Corey L; Bodsworth N; Mindel A; Patel R; Schacker T; Stanberry L
    Herpes; 2007 Jun; 14 Suppl 1():5A-11A. PubMed ID: 17877886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An update on short-course intermittent and prevention therapies for herpes labialis.
    Gilbert S; Corey L; Cunningham A; Malkin JE; Stanberry L; Whitley R; Spruance S
    Herpes; 2007 Jun; 14 Suppl 1():13A-18A. PubMed ID: 17877887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does frequency of genital herpes recurrences predict risk of transmission? Further analysis of the valacyclovir transmission study.
    Kim HN; Wald A; Harris J; Almekinder J; Heitman C; Corey L
    Sex Transm Dis; 2008 Feb; 35(2):124-8. PubMed ID: 17921912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reducing the risk of transmitting genital herpes: advances in understanding and therapy.
    Leone P
    Curr Med Res Opin; 2005 Oct; 21(10):1577-82. PubMed ID: 16238897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of daily valacyclovir suppression on herpes simplex virus type 2 viral shedding in HSV-2 seropositive subjects without a history of genital herpes.
    Sperling RS; Fife KH; Warren TJ; Dix LP; Brennan CA
    Sex Transm Dis; 2008 Mar; 35(3):286-90. PubMed ID: 18157071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Introduction: Is viral shedding a surrogate marker for transmission of genital herpes?
    Sacks SL; Griffiths PD; Corey L; Cohen C; Cunningham A; Dusheiko GM; Self S; Spruance S; Stanberry LR; Wald A; Whitley RJ
    Antiviral Res; 2004 Aug; 63 Suppl 1():S3-9. PubMed ID: 15450380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. One-day regimen of valacyclovir for treatment of recurrent genital herpes simplex virus 2 infection.
    Bavaro JB; Drolette L; Koelle DM; Almekinder J; Warren T; Tyring S; Wald A
    Sex Transm Dis; 2008 Apr; 35(4):383-6. PubMed ID: 18362859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of herpes simplex virus type 2 transmission with antiviral therapy.
    Corey L; Ashley R;
    Herpes; 2004 Aug; 11 Suppl 3():170A-174A. PubMed ID: 15319087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of herpes simplex virus type 2 infection in HIV type 1-infected persons.
    Strick LB; Wald A; Celum C
    Clin Infect Dis; 2006 Aug; 43(3):347-56. PubMed ID: 16804851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HSV shedding.
    Sacks SL; Griffiths PD; Corey L; Cohen C; Cunningham A; Dusheiko GM; Self S; Spruance S; Stanberry LR; Wald A; Whitley RJ
    Antiviral Res; 2004 Aug; 63 Suppl 1():S19-26. PubMed ID: 15450382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Recurrent genital herpes].
    Holub M; Labská K; Roubalová K
    Klin Mikrobiol Infekc Lek; 2008 Apr; 14(2):52-9. PubMed ID: 18756434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Once-daily valacyclovir to reduce the risk of transmission of genital herpes.
    Corey L; Wald A; Patel R; Sacks SL; Tyring SK; Warren T; Douglas JM; Paavonen J; Morrow RA; Beutner KR; Stratchounsky LS; Mertz G; Keene ON; Watson HA; Tait D; Vargas-Cortes M;
    N Engl J Med; 2004 Jan; 350(1):11-20. PubMed ID: 14702423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acyclovir suppression to prevent clinical recurrences at delivery after first episode genital herpes in pregnancy: an open-label trial.
    Scott LL; Hollier LM; McIntire D; Sanchez PJ; Jackson GL; Wendel GD
    Infect Dis Obstet Gynecol; 2001; 9(2):75-80. PubMed ID: 11495557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppressive therapy with valacyclovir in early genital herpes: a pilot study of clinical efficacy and herpes-related quality of life.
    Handsfield HH; Warren T; Werner M; Phillips JA
    Sex Transm Dis; 2007 Jun; 34(6):339-43. PubMed ID: 17065847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical trials of prophylactic and therapeutic herpes simplex virus vaccines.
    Stanberry LR
    Herpes; 2004 Aug; 11 Suppl 3():161A-169A. PubMed ID: 15319086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Virologic characteristics of subclinical and symptomatic genital herpes infections.
    Wald A; Zeh J; Selke S; Ashley RL; Corey L
    N Engl J Med; 1995 Sep; 333(12):770-5. PubMed ID: 7643884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidemiology of genital herpes.
    Kinghorn GR
    J Int Med Res; 1994; 22 Suppl 1():14A-23A. PubMed ID: 8063020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two-day regimen of acyclovir for treatment of recurrent genital herpes simplex virus type 2 infection.
    Wald A; Carrell D; Remington M; Kexel E; Zeh J; Corey L
    Clin Infect Dis; 2002 Apr; 34(7):944-8. PubMed ID: 11880960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genital shedding of herpes simplex virus among men.
    Wald A; Zeh J; Selke S; Warren T; Ashley R; Corey L
    J Infect Dis; 2002 Oct; 186 Suppl 1():S34-9. PubMed ID: 12353185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Herpes simplex virus type 2 transmission: risk factors and virus shedding.
    Wald A
    Herpes; 2004 Aug; 11 Suppl 3():130A-137A. PubMed ID: 15319082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.